文献速递脊柱关节炎其他结缔组织病

肿瘤坏死因子抑制剂治疗与银屑病患者亚临床动脉粥样硬化指标降低相关

Association of Tumor Necrosis Factor Inhibitor Treatment With Reduced Indices of Subclinical Atherosclerosis in Patients With Psoriatic Disease.
PubMed 文献 · Arthritis Rheumatol · 2018-02-06

两阶段研究:第一阶段在319例银屑病或银屑病关节炎患者中评估颈动脉总斑块面积2-3年进展;第二阶段在21例接受TNFi和13例年龄性别匹配未用生物制剂的PsA患者中评估血管炎症。TNFi与男性动脉粥样硬化进展减少相关,与男女血管炎症改善相关。

要点

  • 男性中TNFi与动脉粥样硬化进展减少独立相关(校正β=-2.20,95%CI -3.41至-1.00,P<0.001)。
  • 女性中TNFi与动脉粥样硬化进展无关联(P=0.74)。
  • TNFi组1年时靶本底比(TBR)降低(P=0.03),未用TNFi组无显著变化(P=0.32)。

核心结论

  • TNFi治疗与男性颈动脉斑块进展减少相关,并与男女银屑病患者血管炎症改善相关。

研究设计与样本

  • 两阶段研究:第一阶段在319例银屑病或银屑病关节炎患者中,基线及2-3年后超声评估颈动脉总斑块面积。
  • 第二阶段在21例接受TNFi的PsA患者和13例年龄性别匹配未用任何生物制剂的PsA患者中,基线及1年行18F-氟脱氧葡萄糖-正电子发射断层扫描/计算机断层扫描评估血管炎症(靶本底比TBR)。
  • 两阶段均行多变量回归分析,校正心血管危险因素和他汀类药物使用。

主要发现

  • 第一阶段:男性动脉粥样硬化进展显著高于女性(P<0.001)。
  • 第一阶段:校正心血管危险因素和他汀使用后,TNFi与男性动脉粥样硬化进展减少相关(校正β=-2.20,95%CI -3.41至-1.00,P<0.001)。
  • 第一阶段:女性中TNFi与动脉粥样硬化进展无关联(P=0.74)。
  • 第二阶段:接受TNFi的患者1年时TBR降低(P=0.03);未接受TNFi的患者TBR无显著变化(P=0.32)。
  • 第二阶段:TNFi组主动脉血管炎症改善独立于心血管危险因素(校正β=-0.41,95%CI -0.74至-0.08,P=0.02)。

关键数值与推荐

  • 男性中TNFi与动脉粥样硬化进展减少相关:校正β=-2.20(95%CI -3.41至-1.00),P<0.001。
  • 女性中TNFi与动脉粥样硬化进展无关联:P=0.74。
  • TNFi组1年时TBR降低:P=0.03;未用TNFi组TBR无显著变化:P=0.32。
  • TNFi组主动脉血管炎症改善独立于心血管危险因素:校正β=-0.41(95%CI -0.74至-0.08),P=0.02。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the effect of tumor necrosis factor inhibitors (TNFi) on subclinical cardiovascular disease in patients with psoriatic disease. METHODS: We performed a 2-stage study. In stage 1, carotid total plaque area was assessed in patients with psoriasis or psoriatic arthritis (PsA) (n = 319) by ultrasound at baseline and after 2-3 years. The annual progression rate of atherosclerosis was the outcome of interest. In stage 2, PsA patients receiving TNFi (n = 21) and age- and sex-matched PsA patients not receiving any biologic agent (n = 13) underwent 18 F-fluorodeoxyglucose-positron emission tomography/computed tomography at baseline and 1 year to assess vascular inflammation, measured as target-to-background ratio (TBR). In both stages, multivariable regression analyses adjusted for cardiovascular risk factors and use of statins were performed. RESULTS: In stage 1, men had significantly higher atherosclerosis progression than women (P < 0.001). TNFi was associated with reduced atherosclerosis progression in men after controlling for cardiovascular risk and use of statins (adjusted β = -2.20 [95% confidence interval -3.41, -1.00], P < 0.001). There was no association between TNFi and atherosclerosis progression in women (P = 0.74). In stage 2, patients receiving TNFi had reduced TBR at 1 year (P = 0.03). Those not receiving TNFi had no significant change in TBR (P = 0.32). The improvement in aortic vascular inflammation in the TNFi group was independent of cardiovascular risk factors (adjusted β = -0.41 [95% confidence interval -0.74, -0.08], P = 0.02). CONCLUSION: Our findings indicate that TNFi treatment is associated with reduced progression of carotid plaques in men and improvement in vascular inflammation in both men and women with psoriatic disease.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Eder L, Joshi AA, Dey AK, et al. Association of Tumor Necrosis Factor Inhibitor Treatment With Reduced Indices of Subclinical Atherosclerosis in Patients With Psoriatic Disease. Arthritis Rheumatol. 2018. PMID: 29088580. doi:10.1002/art.40366

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。